Corona Virus
Stay Safe, FollowGuidance
Fetching Location Data…
Vivek Kumar
Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs

Gilead Sciences Inc, an American biopharmaceutical company that researches, develops and commercializes drugs, announced to acquire a pharmaceutical company Immunomedics Inc for $21 billion or $88.00 per share in cash, a move that will help strengthen its drugs portfolio for cancer.

The agreement will provide Gilead with Trodelvy, a first-in-class Trop-2 directed antibody-drug conjugate that was granted accelerated approval by the U.S. Food and Drug Administration in April for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease, the company said.

Gilead anticipates closing the deal during the fourth quarter of 2020.

“Investors may take some time to digest all the deals but these add lots more drivers and clear momentum in oncology and less reliance on HIV. Maintain Buy. We are positively biased on the acquisition as this moves Gilead Sciences (GILD) quickly into a commercial footprint for solid tumors and to prepare for other pipeline,” said Jefferies’ equity analyst Michael J. Yee, who gave a price target of $78.

“We think GILD is in a better place for 2021 than a year ago and the stock is still at 10x and out of favor. Digesting it all, we think a strong launch for Trodelvy, great bladder data, and upside positive data from the Phase III HR+ breast cancer study could be the catalyst that makes Street more confident GILD did a good deal,” Yee added.

Lazard and Morgan Stanley & Co. LLC are acting as financial advisors to Gilead. Centerview Partners LLC and BofA Securities are acting as financial advisors to Immunomedics. Cowen & Company, LLC also provided advice to Immunomedics. Davis Polk & Wardwell LLP is serving as legal counsel to Gilead and Watchell, Lipton, Rosen & Katz is serving as legal counsel to Immunomedics.

Gilead Sciences’ shares ended 2.83% higher at $65.58 on Friday; the stock is up about 1% so far this year, gaining over 5% from 2020 low.

Executive comments

“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” Gilead Chief Executive Officer Daniel O’Day said in a statement.

“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer.”


Gilead Sciences stock forecast

Twenty-two analysts forecast the average price in 12 months at $79.06 with a high forecast of $105.00 and a low forecast of $67.00. The average price target represents a 20.56% increase from the last price of $65.58. From those 22 equity analysts, ten rated “Buy”, 11 rated “Hold” and one rated “Sell”, according to Tipranks.

Gilead Sciences had its price target cut by Truist to $67 from $74.00. SunTrust Banks raised their target price on shares of Gilead Sciences to $74 from $73 and gave the company a “hold” rating. Oppenheimer raised their target price to $105 from $90.

Other equity analysts also recently updated their stock outlook. Mizuho restated a “buy” rating and issued an $81.00 price target. Wells Fargo & Co raised their price target to $76 from $69 and gave the company an “equal weight” rating. Credit Suisse Group lowered their stock price forecast to $73 from $75 and set a “neutral” rating. At last, Cfra raised their price target to $74 from $71 and gave the company a “sell” rating.

We think it is good to hold for now as 100-day Moving Average and 100-200-day MACD Oscillator signal a selling opportunity. However, in the best-case scenario target price $75.

Analyst views

“Our merger analysis suggests mid-to-high single-digit % accretion by 2024E: We built a preliminary acquisition model through 2024, with the following key assumptions: (1) $21B acquisition cost financed with $15 billion in cash and $6 billion in debt; (2) debt interest rate of 3%; (3) cash interest rate of 0.75%; (4) We assume mgt. will spend more to accelerate the pipeline and commercial effort in the near- to mid-term. Overall, we see the acquisition as 5% accretive by 2024E,” Matthew Harrison, equity analyst at Morgan Stanley.

Check out FX Empire’s earnings calendar

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.